LONDON, Dec. 15, 2015 /PRNewswire/ -- Report Details
Outsourced Biopharma Production – New Analysis Showing You Revenue Forecasts
What is the outlook for making biological active pharma ingredients (APIs) under contract?
Visiongain's new report predicts those revenues from 2015. There you see financial data, also assessing trends, technologies, clients' needs and opportunities.
Our study gives you sales forecasts to 2025 at overall world market, submarket and national level. Discover what's happening for those production services – outsourcing and off-shoring for biological drugs (biologics). That way you gain in knowledge, also helping your influence. Biological Drug World Industry and Market Predictions 2015-2025
Please read on to explore that industry and see what future revenue it could generate.
Sales forecasts and discussions to help your research, analyses and decisions
Our study shows you what the future holds for those pharma contract manufacturing organisations (CMOs). You see technological and commercial outlooks for producing medicinal components of biologics. And you discover trends to watch.
Besides revenue forecasting to 2025, our new work shows you recent results, growth rates and market shares. There you find original analysis, exploring trends and developments. You gain 57 tables, 49 charts and two interviews with biopharmaceutical companies.
Gains through analysing those drug-making services – advantages for your work
Why miss information you need? Why struggle to find data? Instead let our analysis guide you through that outsourcing industry's present and future. Your search has just become easier.
Discover where trends in that pharma service industry lead, exploring where the money lies, finding the most lucrative opportunities.
Although no study answers every question, the following sections show how our new investigation benefits your work.
Revenues for the world outsourced biological API market and submarkets
What are the secrets of that industry's progress? You explore the future of the overall world market for outsourcing that biopharma production.
First our report shows you individual revenue forecasting for three main submarkets to 2025, at world level, with discussions:
- Mammalian cell cultures
- Microbial fermentations (culturing)
- Other biotechnological (expression) systems for yielding medical products.
For API revenues, our study breaks its overall world revenue forecast to 2025 into these five therapeutic classes:
- Monoclonal antibodies (mAbs)
- Human growth hormones.
That work explains what stimulates and restrains the biotech API industry, also showing you revenue trends and growth possible. You identify potentials and competition for companies providing those technologies and services to help pharmaceutical companies.
So avoid falling behind, missing business or losing influence. Instead discover how you can benefit by better understanding trends and opportunities from 2015 in that CMO industry.
Our study also gives you geographical revenue predictions for those services.
National markets – what outlooks for production needs and CMOs serving biopharma?
You discover individual revenue forecasts to 2025 for 14 national markets:
- United States (US)
- Germany, France, UK, Italy, Spain (EU5 group) and Switzerland
- Brazil, Russia, India and China (BRIC nations)
- South Korea
For pharma service providers and their customers, many opportunities exist in developed and developing countries. Rising sales of novel biological drugs and biosimilars stimulate demands for outsourced producing of biologics.
There discover how you and your organisation can gain. You find needs and outlooks. Our work explains, also discussing issues affecting that outsourcing of bioproduction.
Developments, challenges and opportunities aff
Download the full report: https://www.reportbuyer.com/product/3247298/
Reportbuyer is a leading industry intelligence solution that provides all market research reports from top publishers